Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect

Preparation of factor VII concentrate using CNBr-activated

  Background: Factor VII concentrates are used in patients with congenital or acquired factor VII deficiency or treatment of hemophilia patients with inhibitors. In this research, immunoaffinity chromatography was used to purify factor VII from prothrombin complex (Prothrombin-Proconvertin-Stuart Factor-Antihemophilic Factor B or PPSB) which contains coagulation factors II, VII, IX and X. The a...

Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven®)

UNLABELLED This case report presents a newly diagnosed congenital factor VII deficiency treated with recombinant activated factor VII (rFVIIa). Congenital factor VII deficiency is a rare autosomal-recessive bleeding disorder that occurs in fewer than 1/500,000 persons. Its presentation can vary from epistaxis to hemarthroses and severe central nervous system bleeding, and correlates poorly with...

Immunogenicity of novel recombinant human activated factor VII analogues on factor VII neonatally-tolerized rats.

Recombinant activated factor VII (rFVIIa; NovoSeven) has been widely used to treat bleeding in patients with haemophilia with inhibitors. To increase the intrinsic activity, analogues of rFVIIa (rFVIIa Q, rFVIIa DVQ, and rFVIIa DVQA) with altered amino acid sequence at or near the active centre have been developed. The immunogenicity of these analogues was tested in a rat immune tolerance model...

Recombinant activated factor VII for acute intracerebral hemorrhage

Acute stroke is the third leading cause of death worldwide, exceeded only by coronary artery disease and cancer. There are two major subtypes of strokeischemic and hemorrhagic with 20-30% of all strokes being hemorrhagic in nature. The incidence of ischemic strokes has steadily declined by virtue of rigorous risk factor modification, but the same has not been possible for hemorrhagic strokes. M...

Rescue recombinant activated factor VII for neonatal subgaleal hemorrhage.